Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
NEXGEL, Inc. (NASDAQ: NXGL) generates news across healthcare, consumer products, and capital markets through developments tied to its ultra-gentle, high-water-content hydrogel technology. The company regularly issues press releases on quarterly financial results, highlighting performance in its contract manufacturing segment and its portfolio of consumer-branded products in health, beauty, and OTC categories.
Investors following NXGL news will see updates on earnings announcements, including revenue trends, gross margin, operating expenses, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Management commentary often discusses demand for branded products, new contract manufacturing agreements, and the impact of partnerships with consumer healthcare companies.
NEXGEL’s news flow also covers strategic and corporate actions. Recent items include the spin-off of select drug delivery application assets into NexGelRx, with NEXGEL retaining a royalty interest, an equity stake, and exclusive hydrogel manufacturing rights. Additional releases have described expanded partnerships, such as the agreement with STADA Arzneimittel AG involving non-dilutive capital to support product launches and marketing efforts, as well as financing transactions like registered direct offerings and concurrent private placements.
Governance and leadership developments are another recurring news theme. NEXGEL has announced board appointments, conference presentations at investor events, and changes in senior finance roles through its press releases and associated SEC filings. Readers of this NXGL news page can review these updates in one place, including information on special meetings of stockholders, strategic advisors to NexGelRx, and other events that shape the company’s direction.
By monitoring the NXGL news feed, market participants can track how NEXGEL’s hydrogel-focused business, partnerships, financings, and governance decisions evolve over time, using official company communications as a primary source.
NEXGEL, a provider of hydrogel products, reported a significant 130% year-over-year revenue growth for 2021, totaling $1.55 million. The fourth quarter saw a revenue increase of 428%, amounting to $533 thousand.
The company completed a $14.2 million IPO and has a cash reserve of $13.35 million as of December 31, 2021, supporting future growth initiatives. Operating expenses rose to $2.58 million, primarily due to one-time costs from the IPO. Despite growth, NEXGEL reported an EBITDA loss of $2.27 million for the year.
NEXGEL, a provider of high-water-content hydrogel products, will report its fourth quarter and full year 2021 financial results on March 21, 2022, after market closure. The company will host a conference call at 4:30 p.m. ET the same day to discuss these results, which will be available for streaming via its Investor Relations website. NEXGEL is known for formulating gentle skin patches utilizing natural ingredients, with over 200 combinations developed over two decades.
NEXGEL, Inc. (NASDAQ: NXGL) launched its new MEDAGEL Bug Bite Relief Patch on February 15, 2022. These patches are designed to provide instant relief for insect bites, using NEXGEL's high-water-content hydrogel technology. Infused with Arnica flower and Lidocaine, the patches are skin-friendly, chemical-free, and latex-free. They stay securely in place without irritation upon removal. The product is now available for purchase on Amazon.com.
NEXGEL, a leader in high-water-content hydrogel products, announced the launch of its new MEDAGEL ClearComfort Hydrogel Patch on January 12, 2022. Designed to prevent and treat foot blisters, these patches utilize advanced hydrogel technology to provide cushioning and protection against friction without leaving sticky residues. Available in customizable shapes, they cater to various footwear needs. CEO Adam Levy emphasized the product's ability to enhance comfort while addressing a common issue faced by consumers globally. The patches can be purchased on Amazon.com.
NEXGEL, a manufacturer of high-water-content hydrogels, provided a year-in-review for 2021, highlighting significant investments in its cGMP facility and the establishment of a robust executive and marketing team. NEXGEL focuses on three business segments: Consumer products like MedaGel and LumaGel, a Custom and White Label strategy for OTC brands, and Medical Devices like the NEXDrape. As of December 31, 2021, the company had 5.6 million shares outstanding and $13.3 million in cash, following a successful IPO that raised $14.2 million.
NexGel, Inc. (NASDAQ: NXGL, NXGLW), based in Langhorne, Pa., specializes in high water-content hydrogels for healthcare and cosmetics. On January 4, 2022, it announced that CEO Adam Levy will present at the virtual H.C. Wainwright Bioconnect Conference from January 10-13, 2022. Levy's presentation will be available on-demand starting January 10th at 7:00 a.m. ET. For details, attendees can register here. NexGel has developed over 200 hydrogel combinations for gentle skin applications.
NexGel, Inc. (NASDAQ: NXGL) has successfully closed its initial public offering, selling 2,585,000 shares of common stock alongside warrants, yielding approximately $14.2 million in gross proceeds. The offering price was set at $5.50 per share. The shares began trading on December 22, 2021. Funds will be allocated for general corporate purposes, including marketing, product development, and potential acquisitions, although no commitments exist currently. Maxim Group LLC served as the sole book-running manager for this offering.
NexGel, Inc. has announced the pricing of its initial public offering (IPO) of 2,585,000 shares at $5.50 per share, generating gross proceeds of approximately $14.2 million. Each share is offered with a warrant for the same amount. The IPO is set to begin trading on Nasdaq under the symbols 'NXGL' and 'NXGLW' on December 22, 2021, with a closing date expected on December 27, 2021. Proceeds will be used for corporate purposes, including product development and potential acquisitions.